Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 6NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 19Other hematologic neoplasm 15Myeloid 2Dermatologic 2Classical hematology 2Plasma cell 1

Conditions

Lymphoma, T-Cell, Cutaneous 2Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Prolymphocytic, T-Cell 1

Interventions

aldesleukin 69Cyclophosphamide 50fludarabine phosphate 36fludarabine 30Interleukin-2 27incomplete Freund's adjuvant 22Ipilimumab 20Biopsy 20Specimen Handling 19Magnetic Resonance Spectroscopy 19MART-1 Antigen 15CTLA-4 Antigen 15sargramostim 14Nivolumab 13Filgrastim 13montanide ISA 51 12Sorafenib 12Interferon-alpha 11pembrolizumab 10trametinib 9Temozolomide 9Bevacizumab 9dabrafenib 8temsirolimus 7Sirolimus 7Gene Expression Profiling 7tanespimycin 6Paclitaxel 6Dacarbazine 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Alemtuzumab × Dermatologic × Clear all
NCT00047060 2023-11-14

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
5 enrolled 18 charts
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT02689453 2022-04-29

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
DermatologicLymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡